** Brokerage Barclays initiates healthcare service provider Astrana Health's ASTH.O coverage with rating "equal-weight"
** Brokerage sets PT at $36, representing 20.6% upside to the stock's last close
** Brokerage says the pending deal to acquire Prospect Health is the largest in the company's history, and the near-term execution risks are real given the scale, complexity and associated debt burden
** "This creates an overhang that tempers our excitement for improving industry dynamics and leaves us on the sidelines for now" - Barclays
** ASTH said in November it entered into a definitive agreement to acquire clinical care provider Prospect Health for $745 million
** Barclays says ASTH is well-positioned to capture improving Medicare Advantage rates, which could potentially reduce costs
** Ten of 12 brokerages rate the stock "buy" or higher, 2 "hold"; their median PT is $50.45, according to data compiled by LSEG
** Stock has fallen 6.1% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。